Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Myriad Genetics (MYGN): Biggest Revenue Beat In 2yrs - Jefferies
February 8, 2017 7:34 AM ESTJefferies analyst, Brandon Couillard, reiterated his Hold rating on shares of Myriad Genetics (NASDAQ: MYGN) even though MYGN posted its biggest revenue beat in >2 yrs. The analyst higlighted the evidence of stability in its flagship hereditary cancer (HC) unit, which grew sequentially (+3%), reversing... More
Ladenburg Thalmann Upgrades Myriad Genetics (MYGN) to Neutral
February 8, 2017 6:42 AM ESTLadenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $15.40 yesterday.
... MoreMyriad Genetics (MYGN) Tops Q2 EPS by 2c
February 7, 2017 4:28 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of... More
